Assessing the incidence and severity of drug adverse events: a Bayesian hierarchical cumulative logit model.

Jiawei Duan, Byron J Gajewski, Paramita Sen, Jo A Wick
Author Information
  1. Jiawei Duan: Global Drug Development, Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, New Jersey, USA. ORCID
  2. Byron J Gajewski: Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas, USA.
  3. Paramita Sen: Global Drug Development, Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, New Jersey, USA.
  4. Jo A Wick: Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas, USA.

Abstract

Detection of safety signals based on multiple comparisons of adverse events (AEs) between two treatments in a clinical trial involves evaluations requiring multiplicity adjustment. A Bayesian hierarchical mixture model is a good solution to this problem as it borrows information across AEs within the same System Organ Class (SOC) and modulates extremes due merely to chance. However, the hierarchical model compares only the incidence rates of AEs, regardless of severity. In this article, we propose a three-level Bayesian hierarchical non-proportional odds cumulative logit model. Our model allows for testing the equality of incidence rate and severity for AEs between the control arm and the treatment arm while addressing multiplicities. We conduct simulation study to investigate the operating characteristics of the proposed hierarchical model. The simulation study demonstrates that the proposed method could be implemented as an extension of the Bayesian hierarchical mixture model in detecting AEs with elevated incidence rate and/or elevated severity. To illustrate, we apply our proposed method using the safety data from a phase III, two-arm randomized trial.

Keywords

References

  1. Pharm Stat. 2016 Mar-Apr;15(2):123-34 [PMID: 26685103]
  2. Stat Methods Med Res. 2004 Jun;13(3):227-38 [PMID: 15198488]
  3. Biometrics. 2009 Jun;65(2):452-62 [PMID: 18510649]
  4. J Biopharm Stat. 2021 Jan 2;31(1):47-54 [PMID: 32589494]
  5. Biom J. 2008 Oct;50(5):837-51 [PMID: 18932142]
  6. J Biopharm Stat. 2013;23(4):829-47 [PMID: 23786257]
  7. Stat Med. 2018 Aug 15;37(18):2667-2689 [PMID: 29736961]
  8. Biometrics. 2004 Jun;60(2):418-26 [PMID: 15180667]
  9. Epidemiology. 2018 Nov;29(6):895-903 [PMID: 30074538]
  10. Stat Med. 2000 Oct 15;19(19):2699-712 [PMID: 10986543]
  11. Biometrics. 2010 Sep;66(3):966-74 [PMID: 19930188]
  12. Stat Med. 2012 Aug 15;31(18):1918-30 [PMID: 22415725]
  13. J Biopharm Stat. 2011 Sep;21(5):1006-29 [PMID: 21830928]

Grants

  1. P30 CA168524/NCI NIH HHS

MeSH Term

Humans
Bayes Theorem
Computer Simulation
Incidence
Logistic Models
Probability
Clinical Trials, Phase III as Topic
Randomized Controlled Trials as Topic

Word Cloud

Created with Highcharts 10.0.0modelhierarchicalAEsBayesiansafetyincidenceseveritymixturecumulativelogitproposedadversetrialmultiplicitynon-proportionaloddsratearmsimulationstudymethodelevatedDetectionsignalsbasedmultiplecomparisonseventstwotreatmentsclinicalinvolvesevaluationsrequiringadjustmentgoodsolutionproblemborrowsinformationacrosswithinSystemOrganClassSOCmodulatesextremesduemerelychanceHowevercomparesratesregardlessarticleproposethree-levelallowstestingequalitycontroltreatmentaddressingmultiplicitiesconductinvestigateoperatingcharacteristicsdemonstratesimplementedextensiondetectingand/orillustrateapplyusingdataphaseIIItwo-armrandomizedAssessingdrugevents:Drugsignaldetection

Similar Articles

Cited By (1)